CVAC - Here's Why You Should Avoid CureVac Stock Like the Plague
On June 30, CureVac (NASDAQ: CVAC) announced final late-stage clinical data for its mRNA coronavirus vaccine candidate CVnCoV. The data was disappointing, to put it mildly, and the stock sold off more than 10% in the after-hours trading session to $66 apiece.
Nobody was more disappointed than the German government, which had invested more than 300 million euros into the vaccine candidate's research and development efforts. And investors should definitely not double down in the face of this blunder -- here's why.
Image source: Getty Images.
For further details see:
Here's Why You Should Avoid CureVac Stock Like the Plague